CORRECTED - Moody's weighs ratings as drug-patent lapses near

(Reuters) - NEW YORK, July 10 - Moody's Investors Service on
Tuesday said a wave of patent expirations on blockbuster drugs
between 2010 and 2012 could lead it to begin lowering its
credit ratings on a number of large U.S. drugmakers several
years before then.




Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.


Read more at Reuters.com Government Filings News

Google, H&R Block, Nokia, Palm, Pfizer, Robert Half: U.S. Equity Preview

(Bloomberg) -- The following is a list of companies whose shares may have unusual price changes in U.S. exchanges today. This preview includes news that broke after exchanges closed yesterday. Stock symbols are in parentheses after company names. Share prices are as of 7:30 a.m. New York time.

Advanced Micro Devices Inc. (AMD US) rose 12 cents to $14.40 in trading before the open of U.S. exchanges. There is speculation the second-largest maker of personal-computer processors may receive an investment from a private equity company.


Read more at Bloomberg Stocks News

Pfizer earnings fall, hurt by charges, generics

(Reuters) - Excluding special items, New York-based Pfizer earned 68 cents per share. Analysts on average expected 57 cents per share, according to Reuters Estimates.




Read more at Reuters.com Business News